News

Age, Education Level Can Affect One’s Ability to Cope with AS, Study Finds

Progressing disease, older age, and lower education can significantly affect ankylosing spondylitis patients’ ability to cope with the challenges and burden associated with their illness, a study has found. Multidisciplinary clinical teams should take these findings into consideration to prevent additional health problems and provide the best care and support…

Simponi or Remicade Treatment Lowers Healthcare Use, Increases Work Productivity in AS Patients, Study Says

A six-month course of treatment with Janssen‘s Simponi (golimumab) or Remicade (infliximab) significantly reduced the use of healthcare resources and increased work productivity in patients with ankylosing spondylitis (AS), according to a study. The study, “Treatment with golimumab or infliximab reduces health resource utilization and increases…

Stopping Infliximab Can Cause Relapses in Ankylosing Spondylitis Patients, Study Says

Stopping treatment with infliximab (brand names, Remsima, Remicade) can lead to relapses in people with ankylosing spondylitis (AS) who are in stable clinical remission, according to a 12-month study. Reintroduction of infliximab treatment is safe; however, it does not result in the same clinical response prior to treatment withdrawal in a significant…

Kidney Issues Should be Considered While Using TNF-Alpha Inhibitors

Despite being rare, kidney complications should be considered in patients with ankylosing spondylitis treated with inhibitors of tumor necrosis factor-alpha (TNF-alpha), such as Remicade (infliximab), according to a case report. The study, “Infliximab-associated focal segmental glomerulosclerosis in a patient with ankylosing spondylitis,” was published in Rheumatology…

Higher Serum BMP-2 Levels may be Linked to the Development of Ankylosing Spondylitis, Meta-Analysis Shows

While serum levels of sclerostin — a protein that regulates bone formation — are identical in patients with ankylosing spondylitis and healthy individuals, serum BMP-2 levels are higher in patients, suggesting a link between these bone-promoting cells and disease development, a meta-analysis study has found. The study, “Serum Sclerostin…